Mp62-01 Water 3: Aquablation Outcomes for Prostate Volumes >150ml vs Prostate Volumes <150ml at a Single Community Institution

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV (MP62)1 May 2024MP62-01 WATER 3: AQUABLATION OUTCOMES FOR PROSTATE VOLUMES >150ML VS PROSTATE VOLUMES <150ML AT A SINGLE COMMUNITY INSTITUTION David Gangwish, Josh Kuperus, Greg Palmateer, Paul Horning, Bernadette Zwaans, Jason Hafron, and Kenneth Peters David GangwishDavid Gangwish , Josh KuperusJosh Kuperus , Greg PalmateerGreg Palmateer , Paul HorningPaul Horning , Bernadette ZwaansBernadette Zwaans , Jason HafronJason Hafron , and Kenneth PetersKenneth Peters View All Author Informationhttps://doi.org/10.1097/01.JU.0001008904.63948.3b.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Aquablation for benign prostatic hyperplasia in clinical trials has been reported in prostate volumes up to 150mL. The objective of this study was to compare Aquablation outcomes in patient's pre-operative (preop) prostate volumes (PV) greater than 150 mL to patients with prostate volumes less than 150 mL. METHODS: Retrospective chart review from September of 2018 to 2022 at a single institution. Variables collected included adverse events (AE) with Clavian-Dindo grades, transfusion rates, surgical retreatment rates, continued medication use post operatively (postop), and American Urologic Association symptom scores (AUASS) with Quality-of-Life indicator (QOL). The Aquablations were then stratified by preop PV<150 ml (PV<150) and ≥150 ml (PV≥150). Independent sample T-Test and Chi-square test were used for data analysis (SPSS 28.0). RESULTS: 174 men treated with Aquablation were included, of these 18 patients were excluded from analysis due to no recorded PV. Thus, 156 patients were included in the analysis: 133 with PV<150 and 33 with PV≥150. PV<150 and PV≥150 were well matched with respect to age in years (72.03 vs 73.09 p=0.396), BMI (27.93 vs 29.38 p=0.226), preop hemoglobin (13.92 vs 13.83 p=0.805), and preop retention (17.2% vs 21.2% p=0.596). There was no significant difference between the groups with respect to length of stay, adverse events, blood transfusion, AUASS/QOL preop and postop, postop Qmax, and postop alpha blocker use (Table 1). PV<150 had 18 AE (14.6%), 2 AE Clavian-Dindo ≥3. PV≥150 had 7 AE (21.2%), 1 AE Clavian-Dindo ≥3. PV<150 compared to PV≥150 had lower retreatment rates (10.7% vs 24.2% p=0.043), postop hemoglobin drop (1.54 vs 2.45 p=0.004), postop use of finasteride (8.9% vs 31.3% p=0.001), and shorter OR times in minutes (57.01 vs 71.58 p=<0.001). CONCLUSIONS: Aquablation therapy for prostate volumes≥150 ml appears to have similar safety and subjective urinary outcomes compared to prostate volumes <150 ml. However, Aquablation for prostate volumes≥150 ml had surgical retreatment rates of 24.2% and post operative finasteride use of 31.3% in our cohort. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1020 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information David Gangwish More articles by this author Josh Kuperus More articles by this author Greg Palmateer More articles by this author Paul Horning More articles by this author Bernadette Zwaans More articles by this author Jason Hafron More articles by this author Kenneth Peters More articles by this author Expand All Advertisement PDF downloadLoading ...